SGMO - Sangamo Therapeutics GAAP EPS of -$0.59 misses by $0.26 revenue of $9.39M misses by $1.01M
2023-11-01 16:04:56 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction
- Sangamo Therapeutics, Inc. (SGMO) Q2 2023 Earnings Call Transcript
- Sangamo Therapeutics Q3 2023 Earnings Preview
- Gene editing stocks gain after Eli Lilly deal amid FDA AdCom
- Seeking Alpha’s Quant Rating on Sangamo Therapeutics
For further details see:
Sangamo Therapeutics GAAP EPS of -$0.59 misses by $0.26, revenue of $9.39M misses by $1.01M